FDA
-
-
-
-
-
-
-
Abivax prices upsized $800M ADS offering at $125 per share
-
-
-
-
-
-
-
Abivax Announces Landmark Phase 3 ABTECT Maintenance Trial Results Evaluating Obefazimod in Moderately to Severely Active Ulcerative Colitis
-
-
-
-
-
-
-
Abivax secures 22 abstracts on inflammatory bowel disease drug at ECCO 2026
-
-
-
-
-
-
-
Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Trial Results with Updated Safety Data
-
-
-
-
-
-
-
Abivax (ABVX) PT Raised to $74 at Leerink Partners
-
-
-
-
-
-
-
Abivax Publishes 2025 Financial Calendar
-
-
-
-
-
-
-
Abivax presents third quarter 2024 key financial information
-
328,249 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

